MODULATING MULTIPLE DRUG RESISTANCE VIA CO-DELIVERY OF NANOPARTICLE by Chen, Xialin et al.
Chen et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2017; 7(3):70-72                                     
ISSN: 2250-1177                                                                                [70]                                                                             CODEN (USA): JDDTAO 
Available online on 15.05.2017 at http://jddtonline.info 
 
Journal of Drug Delivery and Therapeutics 
Open access to Pharmaceutical and Medical research 
 
© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted       
non-commercial use, provided the original work is properly cited 
 
Mini Review 
MODULATING MULTIPLE DRUG RESISTANCE VIA CO-DELIVERY 
OF NANOPARTICLE 
Xialin Chen, Wenzhe Huang, Wei Xiao* 
State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 
222001, China 
__________________________________________________________________________________________________________ 
Article Info: Received 16 March 2017; Review Completed 05 May 2017; Accepted 05 May 2017, Available online 15 May 2017 
 Cite this article as: 
Chen X, Huang W, Xiao W, Modulating multiple drug resistance via co-delivery of nanoparticle, Journal of 
Drug Delivery and Therapeutics. 2017; 7(3):70-72             DOI: http://dx.doi.org/10.22270/jddt.v7i3.1424   
*Address for Correspondence:  
Professor Wei Xiao, State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, 
Jiangsu Kanion Pharmaceutical Co. Ltd., Lianyungang 222001, China   
E-mail: kanionxw2010@126.com, Fax: +86-518-81152367 
___________________________________________________________________________________________________________ 
ABSTRACT 
When various mechanisms in cancer causing cells show resistance towards one or many chemotherapeutics, it hinders the efficacy of 
chemotherapy. This is referred as multidrug resistance. There are several factors that contribute in MDR. This research specifically 
focuses on modulate resistance towards multiple drugs by co-delivery of the nanoparticle. This research review has highlighted 
several delivery systems of nanodrug for overcoming the mechanism followed by MDR. This is done by exploiting, evading or 
neutralizing the pumps of drug efflux. The research essay has specifically discussed five different system categories. These 
categories are Mdr-1 and survivin-targeting, Docetaxel and siRNA, Paclitaxel and curcumin, Doxorubicin and paclitaxel and 
Doxorubicin and PSC 833. Based on the overall discussion, a brief summary is provided. 
Keywords: Drug resistance, nanomedicine, co-delivery, drug delivery. 
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INTRODUCTION 
Cancer is a major factor contributing to several deaths 
across the globe. There has been development of several 
therapeutic strategies such as biological treatments to 
specific pathways of a cell.
1-3
 However, acquired and 
inherent multidrug resistance (MDR) towards drugs of 
chemotherapy is a major challenge for effectively 
treating cancer. 
4,5
Cancer is one of the diseases that are 
prevailing and most impactful presently.
6,7
 
The aim of this essay is to modulate MDR by the use of 
nanoparticle via co-delivery.
8
 In this research essay, 
specific theoretical understanding will be established 
regarding the key concepts relevant to this research 
issue.
9
 A brief discussion on specific topics will be 
presented that include Mdr-1 and survivin-targeting, 
Docetaxel and siRNA, Paclitaxel and curcumin, 
Doxorubicin and paclitaxel and Doxorubicin and PSC 
833 and a brief summary will be provided to conclude 
the essay. 
MDR-1 and Survivin-Targeting 
MDR is the biggest challenge faced in successfully 
completing chemotherapy for the treatment of 
cancer.
10,11
 There is a complicated mechanism involved 
with several factors affecting the same such as proteins 
functioning, ABC transporters and extrude drugs and 
toxins.
12
 Survivin is a new member of the family of 
apoptosis inhibitors.
13
 The functional role is possible in 
the case of apoptosis control and cell division. This is 
up- regulated in case of human cancers that make it a 
new potential target for the treatment of cancer.
14
 For 
the purpose of overcoming MDR, some compounds of 
the small molecule were utilized in the form of 
functional inhibitors like promethazine, cyclosporine A, 
and verapamil. However, their unknown 
pharmacokinetic interaction with toxicities and 
chemotherapeutics restricted their utilization in clinics. 
Additional reports were made that the encapsulation of 
chemotherapeutic agents within nanoparticles could end 
up evading the pumps of drug efflux. This further ended 
up increasing the concentration of the intracellular drug. 
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This rarely showed the effects of anti- tumor. In addition, 
such increased level of concentration did not lead towards 
the proportionately increasing death of cell on blocking the 
apoptosis pathway. It was recently investigated and 
discovered that MDR can enable partial reversal as the 
gene coding expression is silenced. Their experiments on in 
vivo anti-tumor only ended up exhibiting the capability to 
reduce the growth of tumor but without decreasing the 
volume of the tumor.  
Docetaxel and siRNA 
The combination of several therapeutic approaches with 
various mechanisms can be a feasible option for effectively 
treating cancers with combined or synergistic impacts.
15
 
Small interference of RNA was a strong technique with a 
feasible therapeutic option to silence genes targeted in a 
number of diseases.
16
 A number of different therapeutics 
based on siRNA have established for treatment of diseases 
effectively.
17
 However, there cannot be an easy crossing of 
cell membranes in siRNA due to the involvement of 
negative charge and there is a delay in downstream 
effects.
18
 This is in comparison with the conventional 
therapeutics based on protein or small molecule. In 
addition, for being successful in clinically applying siRNA, 
there is a requirement to be effective in delivering vehicles. 
This is crucial for overcoming several barriers in the cell. 
In addition, anti-cancer drug effect of the small molecule is 
fast in comparison with siRNA. This is specific in the 
process of intracellular uptake. Simultaneously, 
nanocarriers will be targeting the drugs while lowering the 
side effect. 
19,20
 Therefore, the set of newly emerging 
therapy based on siRNA with traditional procedures of 
chemotherapy can be considered advantageous. Until yet, a 
number of promising systems for the purposes of co-
delivery are established on the basis of silica, liposomal 
and polymeric based cationic NPs. When compared, non-
viral vectors based on polymer have major benefits in 
comparison with cationic lipids. These advantages are 
specific to physiological stability, large scale production, 
convenience, and safety. There has been an investigation of 
several natural and synthetic cationic polymers as carriers 
of siRNA or gene. These include chitosan, polylysine, and 
polyethyleneimine.  
Paclitaxel and Curcumin 
Curcumin is a polyphenol, also termed as 
diferuloylmethane. Its extraction is done from Curcuma 
longa, which is a perennial herb.
21,22
 This has been 
researched extensively considering its level of therapeutic 
efficacy for a number of disorders that include other 
inflammatory diseases such as cancer and Alzheimer's. On 
extensively researching curcumin, a number of its 
significant functions are revealed.
23
 It comes in interaction 
with a number of proteins inhibiting the performance of 
several kinases and controlling the activated factors of 
transcription. These have specific involvement in survival 
and proliferation of the cell. Irrespective of the 
effectiveness delivered by curcumin, it has limited use in 
the clinic because of its property of hydrophobicity and low 
level of in vivo bioavailability.
24
 However, due to the 
attribution of several therapeutic activities with curcumin, a 
solution to these issues is being searched persistently. 
Delivery systems of nano-sized drugs are identified as 
crucial for overcoming these limitations. In addition, the 
establishment of MDR is among the crucial factors that fail 
several conventional chemotherapies. Three main 
mechanisms are involved in which resistance to the drug is 
acquired by the cancer cells. These are: decreasing the 
intake of the drug with water solubility, intracellular 
modifications impacting the performance of cytotoxic 
drugs like shifted cycle of the cell, and increased efflux of 
hydrophobic drugs dependent on energy.  
Doxorubicin and Paclitaxel 
Chemotherapy is not considered a good option because of 
its undesirable negative implications on the health.
25
 This is 
supported by a low level of bioavailability along with the 
development and emergence of drug resistance. Several 
reports have stated that resistance to multiple drugs will be 
significantly limiting the penetration in tumor tissues by 
anti-cancer drugs.
26
 This leads towards poorly concentrated 
anti-cancer drugs inside the tumor which further fails the 
procedure of chemotherapy.
27
 For the purpose of 
overcoming these limitations, a number of drug delivery 
systems with effective advancement are designed by the 
use of various biocompatible nano-materials. A 
pharmaceutical strategy that is most promising is the 
system of polymeric nanomicelle that has been applied in a 
number of trials. Polymeric micelles are known for 
exhibiting various benefits in comparison with other 
delivery systems of the drug like eased production, longer 
circulation, and ability of targeting. In addition, specific 
protection will be provided to entrapped drugs of anti-
cancer from inactivation in the media of biology. This is 
because of the specific structure of core-shell across the 
system of the polymeric micelle. In collective terms, it has 
been discovered that polymeric micelles are the excellent 
system of nano-drug delivery for chemotherapy. Even 
though polymeric micelles are known for significantly 
affecting the establishment of anti-cancer delivery systems 
loaded with nano drugs, there is a scope of improvement in 
a certain aspect. This is because 40 per cent of tumors in 
humans have the ability to develope resistance against 
agents of chemotherapy.  
Doxorubicin and PSC 833 (Valspodar) 
Chemotherapy can be identified as the mainstream 
approach for treating metastasized and localized 
cancers.
28,29
 However, the establishment of resistance from 
multiple drugs by cancer cells along with side effects of 
systemic toxic take place due to the unspecific localization 
of such drugs to areas without tumor is major challenges.
30
 
There can be the occurrence of MDR by transporters of the 
drug efflux which are active in effluxing out drug. This 
results in reducing the accumulation of intracellular drugs 
and decreasing the level of therapeutic efficacy. The role 
played by P-gp within MDR has resulted in efforts for 
modulating the activity of P-gp.
31
 Several compounds 
known for possessing the inhibitory activities of P-gp are 
synthesized specifically for addressing this problem. 
Inhibitors of the first generation are compounds active 
pharmacologically which provided evidence of inhibiting 
P-gp even though being researched for different purposes.
32
 
However, significant nephrotoxic and immunosuppressive 
effects, cardiac toxicities, poor specificity and low 
potencies for transporters of drug efflux end up limiting 
their clinical application.  
SUMMARY  
There is a requirement of an efficient carrier for delivering 
therapeutic RNA of small interference to the site of a target 
as a number of natural challenges have to be dealt with.
33,34
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Poly is a specific biodegradable polymer that consists of 
base-sensitive or acid ester bonds and amino segments. 
This enables PAEs for condensing the molecules of nucleic 
acids at physiological pH while releasing them across 
cytoplasm at acidic lysosomal or endosomal environment. 
Even though several reports are made to employ PAEs as 
vehicles of RNA, the efficiency of RNAi may not be as 
high as per the expectation set.  
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